Business
Dyadic Appoints Chief Business Officer to Executive Leadership Team
JUPITER, Fla., Nov. 09, 2021 (GLOBE NEWSWIRE) -- Dyadic International, Inc. (“Dyadic”, “we”, “us”, “our”, or the “Company”) (NASDAQ: DYAI), a global
About this update from Dyadic International, Inc.
[{"type":"text","content":"JUPITER, Fla., Nov. 09, 2021 (GLOBE NEWSWIRE) -- Dyadic International, Inc. (“Dyadic”, “we”, “us”, “our”, or the “Company”) (NASDAQ: DYAI), a global biotechnology company focused on further improving, applying and deploying its proprietary C1-cell protein production platform to accelerate development, lower production costs and improve the performance of biologic vaccines, therapeutics and other protein based products today announced the appointment of Joe Hazelton as Chief Business Officer, effective immediately. The creation of this role supports the global commercialization of the Company’s new and existing business initiatives, including corporate strategy, business and corporate development and licensing. Mr. Hazelton will join Dyadic’s executive leadership team reporting directly to President and Chief Executive Officer, Mark Emalfarb. “We are pleased to welcome Joe Hazelton to our executive leadership team in this important role as we enter this critical phase of Dyadic’s corporate development. We are continuing our pursuit of both cutting-edge science and strategic partnerships to expand the application of our C1 protein expression and manufacturing platform. The addition of Joe to lead our commercial efforts reinforces our commitment to maximize the integration of the C1 platform across life sciences and pharma in addition to opportunities in other industries,” said Mark Emalfarb. “I am excited to join Dyadic International as Chief Business Officer. The broad utility of the C1 platform is truly transformational across many industries. As such, Dyadic is uniquely positioned to take advantage of the expanding biologic markets, while at the same time exploiting strategic opportunities within the animal health and other market segments. I have been impressed with the commitment of Dyadic International’s accomplished leadership team and Board of Directors in their effort to accelerate the adoption of the C1 technology within global healthcare and related industries, and I am honored to have the opportunity to be a part of that future,” said Mr. Hazelton. Mr. Hazelton brings over 20 years of pharmaceutical industry experience to Dyadic in key growth areas of product and business development, licensing, and commercialization. He joins Dyadic from Charleston Laboratories, Inc., where he has served as Chief Operating Officer and...